Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715375 | 0.91 | THRB (0.41) | KDM4EALDH1A1THRBPOLBFAAH | |
| SCHEMBL5714637 | 0.89 | ALDH1A1 (0.48) | KDM4EALDH1A1HTR1ADRD2HTR2A | |
| SCHEMBL5715077 | 0.89 | MGLL (0.39) | KDM4EALDH1A1THRBHTR1ADRD2 | |
| SCHEMBL5714476 | 0.86 | HRH3 (0.36) | KDM4EALDH1A1HTR1ADRD2HTR2A | |
| SCHEMBL5714582 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1DRD2POLB | |
| SCHEMBL5714957 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1DRD2FAAHCYP4F2 | |
| SCHEMBL5715300 | 0.84 | HTR1A (0.40) | KDM4EALDH1A1THRBHTR1ADRD2 | |
| SCHEMBL5715203 | 0.84 | KDM4E (0.37) | KDM4EALDH1A1HTR1ADRD2HTR2A | |
| SCHEMBL5714515 | 0.83 | TP53 (0.43) | KDM4EALDH1A1THRBHTR1ADRD2 | |
| SCHEMBL5714874 | 0.82 | KDM4E (0.45) | KDM4EALDH1A1HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006527212-A | — | — | 2006-11-30 | — | — | JP | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | KDM4E 1090/4885ALDH1A1 1504/4885THRB 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.